In a 2026 case report from China, a 34-year-old woman with mild intellectual disability was sent for evaluation of possible narcolepsy. Sleep testing and EEG instead showed epilepsy and moderate obstructive sleep apnea.1 Research Highlights Narcolepsy was ruled unlikely: she took 9.3 minutes on average to fall asleep during daytime nap tests, with no early …
A 2026 meta-analysis of 50 studies estimated that about 1 in 3 people with neurofibromatosis type 1 (NF1) have ADHD (33%), and that roughly 1 in 10 have autism (11%), seizures (11%), depression (13%), or anxiety (12%).1 Every one of those figures sits well above typical population rates, but the individual studies disagreed so widely …
A preprint in 84 older adults with epilepsy found that abnormal Alzheimer's-related blood biomarkers were common, but the biomarker categories did not line up neatly with cognitive impairment. Research Highlights Only 32.1% had normal biomarkers: 27 of 84 older adults with epilepsy were A−T−N− using blood-based amyloid, tau, and neurodegeneration markers.1 AD-continuum profiles were common: …
A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …
A 2026 diagnostic-accuracy preprint found that resting-state EEG network features separated non-lesional epilepsy from functional/dissociative seizures (FDS) at 67.5% balanced accuracy, but the signal was not symmetrical: sensitivity was 81.8% for epilepsy and only 53.3% for FDS.1 In plain clinical terms, the model looked more useful as an epilepsy-supporting marker than as a positive test …
CBD has solid evidence for rare pediatric epilepsies, preliminary signal in anxiety and psychosis, and insufficient evidence for most conditions it’s marketed for.
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …